Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir

Annals of Pharmacotherapy

Volumn 44, Issue 11, 2010, Pages 1850-1854

  Aung, Gregory L ^a   O'Brien, John G ^b   Tien, Pamela G ^c   Kawamoto, Laura S ^d  

^a Yakima Valley Memorial Hospital   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c St Joseph's Medical Center Stockton   (United States)

^d SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Aripiprazole; Darunavir; Duloxetine; Interaction; Ritonavir

Indexed keywords

ARIPIPRAZOLE; BUSPIRONE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DARUNAVIR; DULOXETINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RITONAVIR;

ADULT; ANXIETY DISORDER; ARTICLE; BACKACHE; BLURRED VISION; CASE REPORT; CONFUSION; COORDINATION DISORDER; COUGHING; DEPRESSION; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; FEVER; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHADENOPATHY; MALE; MENINGITIS; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; PIPERAZINES; QUINOLONES; RITONAVIR; SULFONAMIDES; THIOPHENES;

EID: 78049479088     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P139     Document Type: Article

References (25)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services. December 1, 2009; 1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 2010 Jan 9).
2. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008;42:1048-59. DOI 10.1345/aph.1K615
3. Product information. Kaletra (lopinavir/ritonavir). St-Laurent, QC: Abbott Laboratories, December 2009.
4. Product information. Prezista (darunavir). Gurabo, PR: Tibotec Therapeutics, January 2010.
5. Product information. Cymbalta (duloxetine). Indianapolis, IN: Eli Lilly and Company, January 2010.
6. Product information. Abilify (aripiprazole). Princeton, NJ: Bristol-Myers Squibb, November 2009.
7. Waade RB, Christensen H, Rudberg I, et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit 2009;31:233-8. DOI 10.1097/FTD.0b013e3181956726
8. Carstairs SD, Williams SR. Overdose of aripiprazole, a new type of antipsychotic. J Emerg Med 2005;28:311-33. DOI 10.1016/j.jemermed.2004.09.013
9. Yokoi F, Gründer G, Biziere, K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology 2002;27:248-59.
10. Molden E, Lunde H, Lunder N, et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006;28:744-9.
11. Tan HH, Hoppe J, Heard K. A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. Am J Emerg Med 2009;27:607-16. DOI 10.1016/j.ajem.2008.04.020
12. Antia SX, Sholevar EH, Baron DA. Overdoses and ingestions of second-generation antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol 2005;15:970-85. DOI 10.1089/cap.2005.15.970
13. Seifert SA, Schwartz MD, Thomas JD. Aripiprazole (Abilify) overdose in a child. Clin Toxicol (Phila) 2005;43:193-5. DOI 10.1081/CLT-200053097
14. Lofton A, Klein-Schwartz W. Atypical experience: a case series of pediatric aripiprazole exposures. Clin Toxicol (Phila) 2005;43:151-3. DOI 10.1081/CLT-200053095
15. Aceves Avila FJ, Esquivel Nava GA, Gallegos Arreola MP, et al. Cyclophosphamide boluses induce micronuclei expression in buccal mucosa cells of patients with systemic lupus erythematosus independent of cytochrome P450 2D6 status. J Rheumatol 2004;31:1335-9.
16. Hendset M, Hermann M, Lunde H, et al. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007;63:1147-51. DOI 10.1007/s00228-007-0373-6
17. Oosterhuis M, Van De KG, Tenback D. Safety of aripiprazole: high serum levels in a CYP2D6 mutated patient. Am J Psychiatry 2007; 164:175. DOI 10.1176/appi.ajp.164.1.175
18. Lo B, Pizon A. Delayed presentation of an aripiprazole overdose Clin Toxicol (Phila) 2008;46:348-9. DOI 10.1080/15563650701704859
19. Cobaugh DJ, Erdman AR, Booze LL, et al. Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007;45:918-42. DOI 10.1080/15563650701665142
20. Vohora D. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. Curr Opin Investig Drugs 2007;8:531-8.
21. Molina D, Tingle LE, Lu X. Aripiprazole as the causative agent of neuroleptic malignant syndrome: a case report. Prim Care Companion J Clin Psychiatry 2007;9:148-50.
22. Picard LS, Lindsay S, Strawn JR, et al. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 2008;28:530-5. DOI 10.1592/phco.28.4.530
23. Dassa D, Drai-Moog D, Samuelian JC. Neuroleptic malignant syndrome with the addition of aripiprazole to clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:427-8. DOI 10.1016/j.pnpbp.2009.12.022
24. Duggal HS, Kithas J. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine. Am J Psychiatry 2005;162:397-8.
25. Horn JR, Hansten PD, Chan L. New tool to evaluate drug interactions. Ann Pharmacother 2007;41:674-80. DOI 10.1345/aph.1H423